Indaptus Therapeutics is trading 5.26% down at $2.70, with no clear catalyst identified for the October 16 move. - No fresh company announcement surfaced; the private-placement deadline extension was announced September 30, not today. - Biotech was up 2.20%, while available index figures showed mixed moves rather than a clear broad-market drop. - Trading volume and activity details were not provided.